SAN FRANCISCO, Sept. 9, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of Detect Hereditary Pancreatic Cancer, a testing program that ...
SAN FRANCISCO, July 24, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of its Detect programs to provide no-charge genetic testing for ...
SAN FRANCISCO, April 1, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the availability of sponsored genetic testing for patients in the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback